DMAA Drugs Made In America Acquisition Corp. Ordinary Shares
USFinancial ServicesAs of 2026-07-10 16:00
Why DMAA matters now
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) is a US stock in Financial Services. The latest InvestLog snapshot shows $10.66 with +0.05% on the session and $359.4M in market capitalization; recent performance reads 1-month +0.47% and YTD +2.51%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $2.0M, and EPS of $0.06. Investors can compare that operating picture with valuation signals such as P/E 61.55 and FCF yield -0.1%.
Valuation
P/E (TTM)
61.55
PEG
—
P/B
1.04
P/S
0.00
EV/EBITDA
-136.39
DCF Value
—
FCF Yield
-0.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
2.9%
ROA
2.8%
ROIC
-1.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $2.0M | $0.06 |
| Q4 2025 | $0.00 | $213.0K | $0.01 |
| FY 2025 | $0.00 | $5.9M | $0.19 |
| Q3 2025 | $0.00 | $2.2M | $0.07 |
Related Stocks
Company Info
Sector
Financial Services
Industry
Shell Companies
Country
US
Exchange
—
Beta
0.00
Drugs Made In America Acquisition Corp. functions as a special purpose acquisition company, commonly known as a blank check company. Its core mission is to seek out and ultimately acquire one or more existing businesses or their assets. This acquisition strategy encompasses a variety of transactional methods, such as corporate mergers, capital stock exchanges, direct asset purchases, stock acquisitions, or broader corporate reorganizations.